Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs in type 2 diabetes mellitus
NCT04441658Phase 2Unknown
- Sponsor
- Shanghai East Hospital
- Start
- Apr 2020
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai East Hospital. Primary endpoint: The changes in HbA1C level at 24 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04441658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441658.